For Immediate Release

Reliant Pharmaceuticals, LLC Announces $252 Million Closing Of Series D Convertible Preferred Units

December 11, 2003

Liberty Corner, NJ -- Reliant Pharmaceuticals, LLC, a privately held, pharmaceutical company that markets branded, patent-protected pharmaceutical products to primary care physicians, today announced the second closing of its Series D financing. In addition to the $115 million issued in connection with the initial closing, Reliant raised an additional $137 million, bringing the Series D financing round to a total raise of $252 million, including the exchange of $37 million of existing secured debt in the initial round.

Proceeds from the second closing will be used to acquire new product rights, expand the sales force and for general corporate purposes. The second closing included an incremental investment from Invemed Catalyst Fund, which led the round, as well as investments from Baron Growth Fund, Goldman, Sachs & Co. and others.

The company also announced the closing, effective December 3, 2003, of the previously announced purchase of the U.S. rights to the Rythmol® (propafenone HCl) product family from Abbott Laboratories. This acquisition represents a significant expansion of Reliant’s cardiovascular product franchise.

Dr. Ernest Mario, Reliant’s Chairman and Chief Executive Officer, noted, “We expect this to be our last round of private financing on our way to becoming a profitable, self-sustaining business. The $252 million of Series D financing will fund the further expansion of our business through acquisitions like Rythmol®.”

Reliant Pharmaceuticals, LLC is a privately held company founded in 1999 to market branded, patent protected, ethical pharmaceutical products to primary care and targeted specialty physicians. The Company markets a portfolio of products including: Lescol® (fluvastatin) and Lescol® XL (extended release tablets) for cholesterol management under an exclusive promotion agreement with Novartis Pharmaceuticals Corporation; DynaCirc® (isradipine) and DynaCirc CR® (an extended release formulation) for the treatment of hypertension; and Axid® (nizatidine) for the treatment of GERD and peptic ulcers. Reliant has over 900 sales professionals targeting over 80,000 high volume primary care physicians and select specialists throughout the U.S.

Reliant also develops and implements sophisticated life cycle management strategies for its products and is also engaged in late stage development projects. The Company recently received FDA approval for InnoPran XL™, the first bedtime dosed beta-blocker for the treatment of hypertension. The Company has several additional cardiovascular products under development and has in-licensed rights to a novel late stage antiviral.

Print this release.